Schaumburg: Sagent Pharmaceuticals, a privately-held specialty pharmaceutical company, has raised $30 million in the series A financing extension from the existing and new strategic investors. The round was led by Vivo Ventures. This capital will be used to support upcoming product launches, development activities and strategic business objectives.
"Sagent's business model unites extensive pharmaceutical development, regulatory and manufacturing capabilities with the unique strength of our U.S. focused sales and marketing team to provide our hospital and clinical customers with a broad range of the highest quality injectable products," said Jeffrey M. Yordon, Chief Executive Officer, Founder and Chairman of the board of Sagent Pharmaceuticals. "Since our inception in 2006, Sagent has filed more than 70 Abbreviated New Drug Application (ANDAs) to date, with more than 20 products expected in the market by year end."
Sagent Pharmaceuticals focuses on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent currently has more than 200 products in development.
